Posted by on January 28, 2018 4:14 am
Categories: Crispr

Thursday Stock Charts – Harry Boxer,

Amyris, Inc. (AMRS) gained 23 cents, or 4.65%, to 5.18, on 51 667,065 shares traded on Thursday. I like its inverse head-and-shoulder, the rounded bottom, and then it popped a little bit. I think it has a chance to go further. If it continues and gets to 5.50, the targets are in the 6 1/2-7 range.

CRISPR Therapeutics AG (CRSP) had a long base, a strong surge, a little bit of a plug, a pop, pullback, and then boom, it jumped 2.99, or 8%, to 4045, on 915,942 shares traded. In a very sharp angle, it has gone from 17 in mid-December to 40, in just three weeks. That’s a very strong move, and it’s also overbought short-term. If it does run, 50 is the target.

MannKind Corporation (MNKD) had a huge pop of 1.11, or 41%, to 3.80, on 39 million shares traded on Thursday. You can see on the chart that it was in a very narrow coil when it popped and went through 2 layers of prior highs and resistance. For me, I’m looking for a move to 4 1/2, maybe as early as Friday. The swing target, though, is 7.00. This could be very interesting. If it gets momentum like it had previously, it will fly upwards.

Sarepta Therapeutics, Inc. (SRPT) advanced 1.83, or 2.78%, to 67.61, on 1.9 million shares traded on Thursday, reaching another new multi-year high. This is the highest level this stock has reached in 16 years. A 16-year high, folks. If it takes of, it will be up around 81, which is my next target.

On the long side, stocks included Abeona Therapeutics Inc. (ABEO), Adverum Biotechnologies, Inc. (ADVM), Amyris, Inc. (AMRS), Catalyst Biosciences, Inc. (CBIO), Century Aluminum Co. (CENX), California Resources Corporation (CRC), CRISPR Therapeutics AG (CRSP), GRIDSUM HOLDING INC. (GSUM), Harvard Bioscience, Inc. (HBIO), Iovance Biotherapeutics, Inc. (IOVA), ITUS Corporation (ITUS), Kopin Corporation (KOPN), MannKind Corporation (MNKD), Sarepta Therapeutics, Inc. (SRPT), Viking Therapeutics, Inc. (VKTX), and W&T Offshore Inc. (WTI).

Leave a Reply